Kalaris Therapeutics, Inc. (KLRS) Reports Material Event to SEC
Filing Details Kalaris Therapeutics, Inc. (NASDAQ:KLRS) filed a Form 8-K with the Securities and Exchange Commission on July 17, 2026, disclosing a material event. Market Context…
Read more
